Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack
Abstract Background To manage the risk factors and to improve clinical outcomes, patients with stroke commonly receive multiple cardiovascular medications. However, there is a lack of evidence on the optimum combination of medication therapy in the primary care setting after ischemic stroke. Therefo...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-02-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-021-01900-1 |
| _version_ | 1818676753493655552 |
|---|---|
| author | Tian-Tian Ma Ian C. K. Wong Cate Whittlesea Kenneth K. C. Man Wallis Lau Zixuan Wang Ruth Brauer Thomas M. MacDonald Isla S. Mackenzie Li Wei |
| author_facet | Tian-Tian Ma Ian C. K. Wong Cate Whittlesea Kenneth K. C. Man Wallis Lau Zixuan Wang Ruth Brauer Thomas M. MacDonald Isla S. Mackenzie Li Wei |
| author_sort | Tian-Tian Ma |
| collection | DOAJ |
| description | Abstract Background To manage the risk factors and to improve clinical outcomes, patients with stroke commonly receive multiple cardiovascular medications. However, there is a lack of evidence on the optimum combination of medication therapy in the primary care setting after ischemic stroke. Therefore, this study aimed to investigate the effect of multiple cardiovascular medications on long-term survival after an incident stroke event (ischemic stroke or transient ischemic attack (TIA)). Methods This study consisted of 52,619 patients aged 45 and above with an incident stroke event between 2007 and 2016 in The Health Improvement Network database. We estimated the risk of all-cause mortality in patients with multiple cardiovascular medications versus monotherapy using a marginal structural model. Results During an average follow-up of 3.6 years, there were 9230 deaths (7635 in multiple cardiovascular medication groups and 1595 in the monotherapy group). Compared with patients prescribed monotherapy only, the HRs of mortality were 0.82 (95% CI 0.75–0.89) for two medications, 0.65 (0.59–0.70) for three medications, 0.61 (0.56–0.67) for four medications, 0.60 (0.54–0.66) for five medications and 0.66 (0.59–0.74) for ≥ six medications. Patients with any four classes of antiplatelet agents (APAs), lipid-regulating medications (LRMs), angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), beta-blockers, diuretics and calcium channel blockers (CCBs) had the lowest risk of mortality (HR 0.51, 95% CI 0.46–0.57) versus any one class. The combination containing APAs, LRMs, ACEIs/ARBs and CCBs was associated with a 61% (95% CI 53–68%) lower risk of mortality compared with APAs alone. Conclusion Our results suggested that combination therapy of four or five cardiovascular medications may be optimal to improve long-term survival after incident ischemic stroke or TIA. APAs, LRMs, ACEIs/ARBs and CCBs were the optimal constituents of combination therapy in the present study. |
| first_indexed | 2024-12-17T08:48:29Z |
| format | Article |
| id | doaj.art-3b3935a9a975408992eba0e79701c185 |
| institution | Directory Open Access Journal |
| issn | 1741-7015 |
| language | English |
| last_indexed | 2024-12-17T08:48:29Z |
| publishDate | 2021-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj.art-3b3935a9a975408992eba0e79701c1852022-12-21T21:56:09ZengBMCBMC Medicine1741-70152021-02-0119111110.1186/s12916-021-01900-1Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attackTian-Tian Ma0Ian C. K. Wong1Cate Whittlesea2Kenneth K. C. Man3Wallis Lau4Zixuan Wang5Ruth Brauer6Thomas M. MacDonald7Isla S. Mackenzie8Li Wei9Research Department of Practice and Policy, School of Pharmacy, University College LondonResearch Department of Practice and Policy, School of Pharmacy, University College LondonResearch Department of Practice and Policy, School of Pharmacy, University College LondonResearch Department of Practice and Policy, School of Pharmacy, University College LondonResearch Department of Practice and Policy, School of Pharmacy, University College LondonResearch Department of Practice and Policy, School of Pharmacy, University College LondonResearch Department of Practice and Policy, School of Pharmacy, University College LondonMedicines Monitoring Unit (MEMO Research) and Hypertension Research Centre, University of DundeeMedicines Monitoring Unit (MEMO Research) and Hypertension Research Centre, University of DundeeResearch Department of Practice and Policy, School of Pharmacy, University College LondonAbstract Background To manage the risk factors and to improve clinical outcomes, patients with stroke commonly receive multiple cardiovascular medications. However, there is a lack of evidence on the optimum combination of medication therapy in the primary care setting after ischemic stroke. Therefore, this study aimed to investigate the effect of multiple cardiovascular medications on long-term survival after an incident stroke event (ischemic stroke or transient ischemic attack (TIA)). Methods This study consisted of 52,619 patients aged 45 and above with an incident stroke event between 2007 and 2016 in The Health Improvement Network database. We estimated the risk of all-cause mortality in patients with multiple cardiovascular medications versus monotherapy using a marginal structural model. Results During an average follow-up of 3.6 years, there were 9230 deaths (7635 in multiple cardiovascular medication groups and 1595 in the monotherapy group). Compared with patients prescribed monotherapy only, the HRs of mortality were 0.82 (95% CI 0.75–0.89) for two medications, 0.65 (0.59–0.70) for three medications, 0.61 (0.56–0.67) for four medications, 0.60 (0.54–0.66) for five medications and 0.66 (0.59–0.74) for ≥ six medications. Patients with any four classes of antiplatelet agents (APAs), lipid-regulating medications (LRMs), angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), beta-blockers, diuretics and calcium channel blockers (CCBs) had the lowest risk of mortality (HR 0.51, 95% CI 0.46–0.57) versus any one class. The combination containing APAs, LRMs, ACEIs/ARBs and CCBs was associated with a 61% (95% CI 53–68%) lower risk of mortality compared with APAs alone. Conclusion Our results suggested that combination therapy of four or five cardiovascular medications may be optimal to improve long-term survival after incident ischemic stroke or TIA. APAs, LRMs, ACEIs/ARBs and CCBs were the optimal constituents of combination therapy in the present study.https://doi.org/10.1186/s12916-021-01900-1StrokeCombination drug therapyMortalityCohort study |
| spellingShingle | Tian-Tian Ma Ian C. K. Wong Cate Whittlesea Kenneth K. C. Man Wallis Lau Zixuan Wang Ruth Brauer Thomas M. MacDonald Isla S. Mackenzie Li Wei Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack BMC Medicine Stroke Combination drug therapy Mortality Cohort study |
| title | Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack |
| title_full | Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack |
| title_fullStr | Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack |
| title_full_unstemmed | Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack |
| title_short | Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack |
| title_sort | impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack |
| topic | Stroke Combination drug therapy Mortality Cohort study |
| url | https://doi.org/10.1186/s12916-021-01900-1 |
| work_keys_str_mv | AT tiantianma impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT ianckwong impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT catewhittlesea impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT kennethkcman impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT wallislau impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT zixuanwang impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT ruthbrauer impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT thomasmmacdonald impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT islasmackenzie impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack AT liwei impactofmultiplecardiovascularmedicationsonmortalityafteranincidenceofischemicstrokeortransientischemicattack |